Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Cytometry B Clin Cytom. 2023 Jan;104(1):77-86. doi: 10.1002/cyto.b.22044. Epub 2021 Dec 13.


This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Keywords: ELN; consensus; flow cytometry; myelodysplastic syndromes; standardization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Flow Cytometry
  • Humans
  • Myelodysplastic Syndromes* / diagnosis